VivoSeq
Oncology

Malignant Peripheral Nerve Sheath Tumor

21

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Malignant Peripheral Nerve Sheath Tumor is an emerging landscape with 21 programs across 12 companies. The most active players are Bristol-Myers Squibb, Merck & Co., Gynecologic Oncology Group. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

64/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2A

Avyxa

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

14 of 20 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody420%Protein / enzyme210%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed7 · 47%
Recruiting3 · 20%
Terminated3 · 20%
Withdrawn1 · 7%
Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04872543·25 enrolled
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06041516·70 enrolled
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
Recruiting·UUniversity of Minnesota·Phase 1·NCT06693284·8 enrolled
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Active, not recruiting·UUniversity of Florida·Phase 2·NCT04917042·10 enrolled
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Completed·Children's Oncology Group·Phase 2·NCT02452554·62 enrolled
Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Completed·MMayo Clinic·Phase 1·NCT02700230·9 enrolled
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT03433183·21 enrolled
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Completed·SWOG Cancer Research Network·Phase 2·NCT00068367·24 enrolled
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT01661283·25 enrolled
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00304083·48 enrolled
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Completed·SSarcoma Alliance for Research through Collaboration·Phase 1/2·NCT02008877·20 enrolled
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Terminated·Novartis logoNovartis·Phase 2/3·NCT00427583·11 enrolled
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Terminated·OOslo University Hospital·Phase 2·NCT02691026·8 enrolled
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Terminated·—·Phase 1/2·NCT02584647·39 enrolled
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT02986919

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)